Main Menu

Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”

Richard Manning
PharmacoEconomics
November 10, 2020

Partner Richard Manning published a comment on the article “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US,” which was published in PharmacoEconomics in June. Dr. Manning notes that the authors’ conclusion—that multiple drugs have received more than 10 years of exclusivity through the Orphan Drug Act (ODA), which delays cohorts’ access to generic equivalents—merits careful review for several reasons. After discussing those reasons, he shares his own conclusion about the exclusivity conferred by the ODA.

The comment is available here.

Practices

Jump to Page